Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials

被引：0
|
作者：
Meng Li
Yiting Xiong
Chen Liao
Yunyan He
Sijia Duan
Fengming Yi
Yiping Wei
Wenxiong Zhang
机构：
[1] The Second Affiliated Hospital of Nanchang University,Department of Thoracic Surgery
[2] Nanchang University,Jiangxi Medical College
[3] The Second Affiliated Hospital of Nanchang University,Department of Breast Surgery
[4] The Second Affiliated Hospital of Nanchang University,Department of Oncology
来源：
Breast Cancer Research and Treatment | 2020年 / 180卷
关键词：
Anastrozole; Fulvestrant; Breast cancer; Hormone receptor positive; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：269 / 278
页数：9
相关论文
共 50 条
  • [1] Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials
    Li, Meng
    Xiong, Yiting
    Liao, Chen
    He, Yunyan
    Duan, Sijia
    Yi, Fengming
    Wei, Yiping
    Zhang, Wenxiong
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 269 - 278
  • [2] A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
    Pui San Tan
    Haaland, Benjamin
    Montero, Alberto J.
    Lopes, Gilberto
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (03) : 961 - 965
  • [3] A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
    Pui San Tan
    Benjamin Haaland
    Alberto J. Montero
    Gilberto Lopes
    Breast Cancer Research and Treatment, 2013, 138 : 961 - 965
  • [4] FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer
    Ellis, M. J.
    Bondarenko, I.
    Trishkina, E.
    Dvorkin, M.
    Panasci, L.
    Manikhas, A.
    Shparyk, Y.
    Cardona-Huerta, S.
    Cheung, K-L.
    Philco-Salas, M. J.
    Ruiz-Borrego, M.
    Shao, Z.
    Noguchi, S.
    Grinsted, L. M.
    Fazal, M.
    Stuart, M.
    Robertson, J. F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naive, hormone receptor-positive (HR plus ) advanced breast cancer (FALCON)
    Robertson, J.
    Shao, Z.
    Noguchi, S.
    Singh, S.
    Subramaniam, S.
    Ellis, M. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S339 - S340
  • [6] Anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer: A meta-analysis.
    Tan, Pui San
    Haaland, Benjamin
    Montero, Alberto J.
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
    Xu, Liang
    Yan, Ningning
    Li, Zhihua
    Luo, Lihua
    Wu, Xiaobo
    Liu, Qiuming
    Xu, Yingchun
    Cao, Yali
    ONCOTARGETS AND THERAPY, 2018, 11 : 8389 - 8398
  • [8] Fulvestrant 250mg versus Anastrozole 1 mg in the Treatment of Advanced Breast Cancer: a Meta-Analysis of Randomized Controlled Trials
    Gong, Dan-Dan
    Man, Chang-Feng
    Xu, Juan
    Fan, Yu
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (05) : 2095 - 2100
  • [9] Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials
    Wen-Zhao Lin
    Qi-Ni Xu
    Hong-Biao Wang
    Xu-Yuan Li
    Breast Cancer, 2017, 24 : 345 - 352
  • [10] Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials
    Lin, Wen-Zhao
    Xu, Qi-Ni
    Wang, Hong-Biao
    Li, Xu-Yuan
    BREAST CANCER, 2017, 24 (03) : 345 - 352
12345